Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compounding Naltrexone for the Treatment of Autism

Author(s):  Wynn Tom, Brunetti Sarah

Issue:  Jul/Aug 2009 - Homone Replacement Therapy
View All Articles in Issue

Page(s):  296-299

Compounding Naltrexone for the Treatment of Autism Page 1
Compounding Naltrexone for the Treatment of Autism Page 2
Compounding Naltrexone for the Treatment of Autism Page 3
Compounding Naltrexone for the Treatment of Autism Page 4

Download in electronic PDF format for $75

Abstract:  Autism is a complex disorder that affects children. Children who present with symptoms of autism require a comprehensive evaluation by a multidisciplinary team including a psychologist, neurologist, psychiatrist, speech therapist, and other professionals who diagnose children with autism spectrum disorders. Following the diagnosis, a treatment plan is developed, which in most cases involve educational and behavioral interventions and medications. The multidisciplinary team then expands to a team of professionals to treat the disorder, the team of which includes a pharmacist. Anxiety, depression, obsessive-compulsive disorder, behavioral problems, seizures, impulsivity, and hyperactivity are the main symptoms of autism that have in many cases been successfully minimized and in some cases alleviated by proper medication.

Related Keywords: Tom Wynn, RPh, Sarah Brunetti, autism spectrum disorder, children, neurotransmitters, opioid excess, beta endorphins, brain development, naltrexone hydrochloride, opioid antagonist, narcotic inhibitor, case reports, formulation

Related Categories: FORMULATIONS, MENTAL HEALTH, PEDIATRICS, CASE REPORTS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compounding Naltrexone for the Treatment of Autism
Wynn Tom
, Brunetti Sarah
Jul/Aug 2009
Pg. 296-299

Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Muller George
, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
Jul/Aug 2018
Pg. 270-278

Naltrexone Hydrochloride 0.5 mg/mL and 5.0 mg/mL in SuspendIt Suspension
Allen Loyd V Jr
May/Jun 2021
Pg. 233

Naltrexone Hydrochloride 50-mg Capsules
Allen Loyd V Jr
May/Jun 2013
Pg. 235

Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base SuspendIt
Pramar Yashoda V
, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Morris Tommy C, Graves Richard A
Mar/Apr 2019
Pg. 157-162

Opioids: A Review of the Pharmacology
Ford Peter R
Jan/Feb 2000
Pg. 17-20

Topical Secretin for the Treatment of Autism
King Erin
, Toney Steve
Nov/Dec 2001
Pg. 436-437

Autism in Children
Cave Stephanie
Jan/Feb 2001
Pg. 18-19

PostScription: Compounding Pharmacies and the Successful Treatment of Autism
Neurander James A
Nov/Dec 2005
Pg. 487-488

Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients
Sturn Kayla M
, Collin Michael
May/Jun 2016
Pg. 197-201

Case Reports on the Use of Aloe Vera, Naltrexone, and Topiramate for the Treatment of Scars
Harris Kylie
, Wright Edward
Nov/Dec 2021
Pg. 482-485

Unlocking Autism: Is Compounding the Key?
Vail Jane
Nov/Dec 2005
Pg. 413-420

Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders
Ploesser Jennifer
, Weinstock Leonard B, Thomas Erin
Mar/Apr 2010
Pg. 171-173

Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management
Rodriguez Franklin
, Carvalho Maria, Banov Fabiana
Nov/Dec 2023
Pg. 468-473

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Riepl Mike
, Kaiser Joe
Jul/Aug 2023
Pg. 284-293

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Mar/Apr 2024
Pg. 100-109

The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia
Cote Brianna
, Ross Bethany, Fortner Jeff, Rao Deepa
May/Jun 2018
Pg. 252-256

Chemical Stability of Naltrexone Hydrochloride Injection
Gupta Vishnu D
May/Jun 2008
Pg. 274-275

Return to Top